1404 Participants Needed

Levonorgestrel IUD for Birth Control

Recruiting at 7 trial locations
SE
CS
Overseen ByCorinne Sexsmith
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the Levonorgestrel 52 mg IUD for effectiveness in emergency contraception and same-day start in real-life settings. It targets individuals needing this IUD either after unprotected sex within the last 5 days or to start it more than a week after their last period, without recent unprotected sex. Participants must be fluent in English or Spanish and have a cell phone for study communication. The trial aims to determine if the IUD prevents pregnancy one month after placement. As a Phase 4 trial, this research seeks to understand how the already FDA-approved and effective treatment benefits more patients.

Do I have to stop taking my current medications for the trial?

The trial requires that you stop using any contraceptive pills, patches, vaginal rings, contraceptive implants, or IUDs for at least 4 weeks before participating. You also cannot have used oral emergency contraception in the last 5 days or injectable hormonal contraceptives in the last 6 months.

What is the safety track record for the Levonorgestrel 52 mg Intrauterine Device?

Research has shown that the levonorgestrel 52 mg intrauterine device (IUD) is both effective and safe, with successful use for up to 8 years. Many studies confirm it is well-tolerated and has a strong safety record.

In past studies, thousands of women used the levonorgestrel IUD, and it received approval for long-term use, indicating thorough safety testing. Some side effects, such as spotting or cramping, can occur, but serious issues are rare. The FDA has already approved this IUD for regular birth control, further supporting its safety.

Overall, for those considering joining this trial, the levonorgestrel IUD is a well-researched and trusted option.12345

Why are researchers enthusiastic about this study treatment?

Researchers are excited about using the Levonorgestrel 52 mg IUD for emergency contraception because it offers a novel, long-term solution compared to traditional emergency contraceptive pills, like Plan B, which only provide short-term coverage. Unlike standard options that require repeated dosing or do not provide ongoing contraception after the emergency use, this IUD starts working immediately and continues to prevent pregnancy for up to several years. This dual capability—immediate emergency contraception and long-term prevention—sets it apart and could significantly enhance convenience and effectiveness for users.

What is the effectiveness track record for the Levonorgestrel 52 mg IUD for emergency contraception and same-day start use?

Research has shown that the Levonorgestrel (LNG) 52 mg Intrauterine Device (IUD) is highly effective for birth control. Studies indicate it prevents pregnancy more than 99.8% of the time in the first year and over 99.3% of the time over five years. A review of multiple studies found the pregnancy rate with the LNG IUD to be just 0.3%, making it more effective than some other IUDs. Users have reported satisfaction with it, even beyond the usual five-year period. In this trial, participants will receive the LNG IUD as a same-day start or for emergency contraception, exploring its effectiveness in these contexts.36789

Who Is on the Research Team?

DT

David Turok, MD, MPH

Principal Investigator

University of Utah

Are You a Good Fit for This Trial?

Inclusion Criteria

Meet clinic eligibility for IUD placement
Have a LNG 52 mg IUD placed for either emergency contraception (had unprotected intercourse in the last 5 days) OR Same-day start, >7 days since the onset of last menstrual period and have no report of unprotected intercourse in the last 5 days
Negative high sensitivity urine pregnancy test prior to IUD placement.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive the Levonorgestrel 52 mg IUD for emergency contraception or same-day start

4 weeks
1 visit (in-person) for IUD placement

Follow-up

Participants are monitored for safety and effectiveness after IUD placement

4 weeks
Weekly text surveys and a final survey at 28 days

What Are the Treatments Tested in This Trial?

Interventions

  • Levonorgestrel 52 MG Intrauterine System

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: 52 mg LNG IUD Same Day Start or ECExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Utah

Lead Sponsor

Trials
1,169
Recruited
1,623,000+

Planned Parenthood Federation of America

Collaborator

Trials
17
Recruited
21,600+

Citations

findings from the Mirena Extension Trial

At the end of year 8, most (98.7%, 220/223) of the participants who completed the study remained satisfied with the continued use of the 52-mg ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/36096186/

findings from the Mirena Extension Trial

During extended use beyond 5 years and up to 8 years, participants reported a decrease in the mean number of bleeding or spotting days with approximately half ...

Mirena® IUD Efficacy | Official HCP Site

Reliable pregnancy protection for up to 8 years. 1 Over 99.8% contraceptive efficacy at year 1 and over 99.3% cumulative efficacy over 5 years.

a meta-analysis of randomized controlled trials

The pregnancy rate is 1.2% for Cu-IUDs >250 mm2 and 0.3% for LNG (52 mg) IUD. Further meta-analysis of six studies revealed that the risk of ...

Contraception with levonorgestrel-releasing intrauterine ...

Recent RCTs indicated that the LNG (52 mg) IUD was more effective than the Cu (380 mm2 and 220 mm2) IUDs in preventing unintended pregnancies., However ...

6.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/35569516/

Levonorgestrel 52 mg intrauterine system efficacy and ...

The levonorgestrel 52 mg intrauterine system is highly effective over 8 years of use and has an excellent extended safety profile.

7.

mirenahcp.com

mirenahcp.com/safety

Mirena® IUD Safety Information | Official HCP Site

Review the safety and full prescribing information for Mirena® (levonorgestrel-releasing intrauterine system) 52 mg IUD.

Mirena® (levonorgestrel-releasing intrauterine system)

In study sites having verifiable data and informed consent, 1169 women 18 to. 35 years of age at enrollment used Mirena for up to 5 years, for a total of 45,000 ...

Levonorgestrel (intrauterine route) - Side effects & uses

It works by stopping a woman's egg from fully developing each month. The egg can no longer accept a sperm and fertilization (pregnancy) is prevented.